Prasugrel Outperforms Clopidogrel In Head-To-Head Test For Recurrent Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly and Daiichi Sankyo await Sept. 26 FDA action date for anti-platelet drug slated to take on Bristol’s Plavix.